FibroGen, Inc.
http://www.fibrogen.com
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From FibroGen, Inc.
Deal Watch: AzurRx Expands GI Pipeline With Buyout Of Partner First Wave
Stock-and-cash deal valued at $229m brings AzurRx rights to niclosamide in additional indications. Boehringer Ingelheim partners with Twist on therapeutic antibody discovery.
FibroGen May Have A New Opening For Roxadustat In The US
The company announced positive Phase II data for roxadustat in chemotherapy-induced anemia.
European Approval For Roxadustat Is Silver Lining For FibroGen
The EU approval is good news for FibroGen and marketing partner Astellas, but was expected, and still leaves it pondering its future after FDA knock-back.
Ellis Unger’s US FDA Farewell Address?
The US FDA advisory committee review of AstraZeneca/FibroGen’s roxadustat for anemia was the last in the long tenure of Office of Cardiology Director Ellis Unger. His opening remarks struck a valedictory tone.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Medical Devices
- Biomaterials
- Other Names / Subsidiaries
-
- FibroGen China Anemia Holdings Ltd.
- FibroGen (China) Medical Technology Development Co., Ltd.
- FibroGen Europe Oy
- FibroGen International (Cayman) Limited
- FibroGen International (Hong Kong) Limited
- Skin Sciences, Inc.